China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

The funding will be used to provide purchase commitments to manufacturers so they can scale up test production.

Meridian Bioscience announced on Wednesday that its Revogene SARS-CoV-2 test has received Emergency Use Authorization from the US Food and Drug Administration.

Britain said it would recognise COVID-19 vaccines on the World Health Organization's Emergency Use Listing later this month.

Viome Life Sciences said Wednesday that it has raised $54M in pre-series C convertible funding with participation from existing and new investors. Added to prior funding, including a series B round in November 2019, the company said it has raised over $125M in total.

Point-of-care diagnostics firm LumiraDx on Wednesday reported a sharp year-over-year increase in revenues for the third quarter on sales of test strips for its COVID Ag SARS-CoV-2 antigen test.

GE announced today what Chairman and CEO Larry Culp called a “defining moment,” with plans to form three industry-leading, global public companies focused on the growth sectors of aviation, healthcare and energy.

Castle Biosciences reported after the close of the market on Monday that its third quarter revenues rose 54 percent year over year, thanks to a 62 percent increase in the number of tests delivered during the quarter.

Invitae reported after the close of the market on Monday that its third quarter revenues increased 66 percent year over year, exceeding the consensus Wall Street estimate.

Blending experts from molecular genetics, chemistry and health sciences, researchers at the University of California San Diego have created a rapid diagnostic technology that detects SARS-CoV-2, the coronavirus that causes COVID-19.

Whole genome sequencing from a single blood test picks up 31% more cases of rare genetic disorders than standard tests, shortening the ‘diagnostic odyssey’ that affected families experience, and providing huge opportunities for future research.